Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Central nervous system cancers.

Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1114-51.

2.

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB.

J Clin Oncol. 2000 Feb;18(3):636-45.

PMID:
10653879
4.

Central Nervous System Cancers, Version 1.2015.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM.

J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202.

PMID:
26483059
5.

The changing management of low-grade astrocytomas and oligodendrogliomas.

Agulnik M, Mason WP.

Hematol Oncol Clin North Am. 2006 Dec;20(6):1249-66.

PMID:
17113461
6.

Novel diagnostic and therapeutic approaches to malignant glioma.

Weller M.

Swiss Med Wkly. 2011 May 24;141:w13210. doi: 10.4414/smw.2011.13210. Review.

7.

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M.

J Natl Compr Canc Netw. 2014 Nov;12(11):1517-23.

8.

Malignant gliomas.

Burton EC, Prados MD.

Curr Treat Options Oncol. 2000 Dec;1(5):459-68. Review.

PMID:
12057153
9.

Nogo-A: a useful marker for the diagnosis of oligodendroglioma and for identifying 1p19q codeletion.

Marucci G, Di Oto E, Farnedi A, Panzacchi R, Ligorio C, Foschini MP.

Hum Pathol. 2012 Mar;43(3):374-80. doi: 10.1016/j.humpath.2011.05.007.

PMID:
21835431
10.

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN.

J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9.

PMID:
9776413
11.

Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response.

Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC.

J Clin Oncol. 2006 Mar 10;24(8):1246-52. Review.

PMID:
16525179
12.

Evidence-based adjuvant therapy for gliomas: current concepts and newer developments.

Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST.

Indian J Cancer. 2009 Apr-Jun;46(2):96-107. Review.

13.

TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.

Chan AK, Yao Y, Zhang Z, Chung NY, Liu JS, Li KK, Shi Z, Chan DT, Poon WS, Zhou L, Ng HK.

Mod Pathol. 2015 Feb;28(2):177-86. doi: 10.1038/modpathol.2014.94.

14.

1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.

Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S.

Neuro Oncol. 2013 Jun;15(6):775-82. doi: 10.1093/neuonc/not027.

15.

[Histological and molecular classification of gliomas].

Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Review. French.

PMID:
18565348
16.

Treatments for astrocytic tumors in children: current and emerging strategies.

Burzynski SR.

Paediatr Drugs. 2006;8(3):167-78. Review.

PMID:
16774296
17.

Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.

Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, Mokhtari K, van Duinen SG, Teepen JL, Wesseling P, Vandenbos F, Grisold W, Sipos L, Mirimanoff R, Vecht CJ, Allgeier A, Lacombe D, van den Bent MJ.

Neuro Oncol. 2009 Dec;11(6):737-46. doi: 10.1215/15228517-2009-011.

18.

Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.

Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW.

Front Biosci. 2003 Jan 1;8:a1-9.

PMID:
12456321
19.

Diffusely infiltrative low-grade gliomas in adults.

Lang FF, Gilbert MR.

J Clin Oncol. 2006 Mar 10;24(8):1236-45. Review.

PMID:
16525178
20.

Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.

Marko NF, Prayson RA, Barnett GH, Weil RJ.

Genomics. 2010 Jan;95(1):16-24. doi: 10.1016/j.ygeno.2009.09.007.

Items per page

Supplemental Content

Support Center